IP Verse

Stable Formulations Of Antibodies To Human Programmed Death Receptor Pd-1 And Related Treatments

Patent No. EP2691112 (titled "Stable Formulations Of Antibodies To Human Programmed Death Receptor Pd-1 And Related Treatments") was filed by Merck Sharp & Dohme on Mar 29, 2012. The application was issued on May 23, 2018.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
KNIG SZYNKA TILMANN VON RENESSEFeb 25, 2019KNIG SZYNKA TILMANN VON RENESSE
KONIG SZYNKA TILMANN VON RENESSEFeb 25, 2019HOFFMANN EITLE
KONIG SZYNKA TILMANN VON RENESSEFeb 25, 2019KONIG SZYNKA TILMANN VON RENESSE DUSSELDORF
KONIG SZYNKA TILMANN VON RENESSEFeb 25, 2019KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORF
STRAWMANFeb 22, 2019D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2691112

MERCK SHARP & DOHME
Application Number
EP12763896A
Filing Date
Mar 29, 2012
Status
Granted And Under Opposition
Apr 20, 2018
Publication Date
May 23, 2018
External Links
Slate, Register , Google Patents